Product Information
ARFORMOTEROL 15 MCG/2 ML SOLN is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.6145 per ML under NDC 00093595556. Its NADAC has been published 240 times since Jan 19, 2022.
FDA first approved this application on Nov 9, 2021.
The High Outlier badge above means this manufacturer's average price in the Arformoterol tartrate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
15 ug/2mL
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093595556
Classification
Generic
Dosage Form
SOLUTION
Route
RESPIRATORY (INHALATION)
Effective Date
8/19/2026
Active Ingredients
ARFORMOTEROL TARTRATEApproval Type
Generic (ANDA)
FDA Application
ANDA200293FDA Approved
11/9/2021
On Market Since
12/6/2021
Pharmacological Classes
Price Statistics
The NADAC for ARFORMOTEROL 15 MCG/2 ML SOLN has been published 240 times since Jan 19, 2022, and over the history we have for it it has declined 80.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6145 per ML |
|---|---|
| All-time high | $3.4638 (Mar 16, 2022) |
| All-time low | $0.5426 (Jun 17, 2026) |
| 52-week high | $0.7009 |
| 52-week low | $0.5426 |
| Median price | $0.9627 |
| Average price | $1.2149 |
| Largest weekly change | -41.0% (Jul 17, 2024) |
| Weeks tracked | 240 |
| Tracking since | Jan 19, 2022 |
1W
N/A
1M
N/A
3M
+13.3%
6M
-5.9%
1Y
-10.9%
3Y
-48.7%
5Y
N/A
All
-80.1%
Last surveyed Aug 19, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Arformoterol tartrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
beta2-Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ARFORMOTEROL 15 MCG/2 ML SOLN?
The current National Average Drug Acquisition Cost (NADAC) for ARFORMOTEROL 15 MCG/2 ML SOLN, manufactured by Teva Pharmaceuticals USA Inc., is $0.6145 per ML (NDC 00093595556), effective Aug 19, 2026.
How has the price of ARFORMOTEROL 15 MCG/2 ML SOLN changed over time?
Over the history we have for it, the NADAC for ARFORMOTEROL 15 MCG/2 ML SOLN has declined 80.1%. It has been tracked across 240 weekly CMS publications since Jan 19, 2022.
What are the highest and lowest recorded NADAC prices for ARFORMOTEROL 15 MCG/2 ML SOLN?
Since Jan 19, 2022, the NADAC for ARFORMOTEROL 15 MCG/2 ML SOLN has ranged from a low of $0.5426 (Jun 17, 2026) to a high of $3.4638 (Mar 16, 2022), with a median of $0.9627 per ML.
Are there cheaper alternatives to ARFORMOTEROL 15 MCG/2 ML SOLN?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ARFORMOTEROL 15 MCG/2 ML SOLN in a comparable dosage form, but none are currently priced below it.
Who manufactures ARFORMOTEROL 15 MCG/2 ML SOLN?
ARFORMOTEROL 15 MCG/2 ML SOLN (NDC 00093595556) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.